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Abstract: Vitamin D receptor (VDR) and liver X receptor (LXR) are nuclear receptors, which regulate gene transcription 
upon binding of their speciﬁ  c ligands. VDR seems to play a role in the regulation of prostate cancer cell proliferation. ATP-
binding cassette transporter A1 (ABCA1) is known to be a target gene of LXR and it has been reported to be inhibited by 
androgen and to be involved in the regulation of LNCaP proliferation. We ﬁ  nd that calcitriol (1α,25(OH)2D3) inhibits both 
basal and a LXR agonist, TO-901317, induced ABCA1 mRNA expression but has no effect on the mRNA expression of 
ATP-binding cassette transporter G1 (ABCG1), LXRα nor LXRβ. TO-901317 increases both basal and calcitriol induced 
25-hydroxyvitamin D3-24-hydroxylase (CYP24) mRNA expression and it slightly but signiﬁ  cantly inhibits VDR mRNA 
expression. The inhibition of ABCA1 by calcitriol appears to be androgen-independent. Cell growth assay shows that when 
each of calcitriol and 5α-dihydrotestosterone (DHT) was co-treated with ABCA1 blocker, glybenclamide, cell-growth is 
signiﬁ  cantly decreased compared to their own treatments respectively. Our study suggests a possible interaction between 
calcitriol and TO-901317 in LNCaP cells. Alike DHT, the inhibition of ABCA1 by calcitriol may be involved in its regula-
tion of LNCaP growth.
Abbreviations: ABCA1/G1: ATP-binding cassette transporter A1/G1; LXR: Liver X receptor; VDR: vitamin D receptor; 
CYP24: 25-hydroxyvitamin D3-24-hydroxylase.
Keywords: mRNA regulation, ABCA1, CYP24, calcitriol, LXR agonist, interaction, cell proliferation
Introduction
Vitamin D receptor (VDR) is a ligand dependent transcription factor that belongs to a nuclear receptor 
family. Calcitriol (1α,25(OH)2D3) is an active form of vitamin D3, which mediates its biological 
activities through VDR. 25-hydroxyvitamin D3-24-hydroxylase (CYP 24) is the most sensitive vitamin 
D3 responsive gene (Wang et al. 2005; Wood et al. 2004) and thus its ﬂ  uctuate expression after VDR 
activation has been utilized for evaluation of VDR signaling changes (Dunlop et al. 2005). It has been 
reported that calcitriol inhibits prostate cancer growth by androgen-dependent and androgen-indepen-
dent mechanisms (Zhao et al. 2000).
Liver X receptors, LXRα and LXRβ are also ligand-dependent transcription factors and belong to 
the nuclear receptor family. Many of the target genes for LXRs are involved in cholesterol and fatty 
acid metabolism pathways. Major cholesterol-related targets of LXRs include the ATP-binding cassette 
transporter family members such as ABCA1, ABCG1, ABCG5 and ABCG8. ABCA1 is encoded by the 
gene that is mutated in Tangier disease (Brooks-Wilson et al. 1999; Rust et al. 1999), which is featured 
by low or absence of HDL-C and reduced total cholesterol (Serfaty-Lacrosniere et al. 1994) and is 
associated with increased susceptibility to atherosclerosis (Maxﬁ  eld and Tabas, 2005). Interestingly, 
recent studies show that LXR agonist inhibits tumor growth and progression of LNCaP prostate cancer 
cells (Chuu et al. 2006; Fukuchi et al. 2004b) and androgenic inhibition of ABCA1 is involved in the 
regulation of prostate cancer growth (Fukuchi et al. 2004a).
Our previous study (Wang and Tuohimaa, 2007) suggests that LXR, VDR and androgen receptor 
(AR) signaling form a complex interaction in the prostate cancer LNCaP cells. In the present study, we 
aimed to investigate whether VDR ligand, calcitriol, had effects on the expression of LXR target gene, 98
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ABCA1, and if any, the physiological consequences 
concerning LNCaP cell growth; whether LXR 
agonist, TO-901317, had effects on the expression 
of VDR target gene, CYP24.
Materials and Methods
Reagents
1α,25(OH)2D3, was obtained from Leo Pharma-
ceuticals (Ballerup, Denmark). TO-901317, 
glybenclamide, cycloheximide (CHX) and RPMI-
1640 medium were purchased from Sigma-Aldrich 
(Saint Louis, Missouri, U.S.A.). 5α-dihydrotestos-
terone (DHT) was obtained from Merck (Darmstadt, 
Germany). Bicalutamide was obtained from 
AstraZeneca (London, U.K.). FBS was purchased 
from Gibco-BRL (Life Technology, Paisley, 
Scotland). TRIzoL reagent was purchased from 
Invitrogen (Carlshad, U.S.A.). High Capacity DNA 
Archive Kit and SYBR Green PCR Master Mix 
Kit were purchased from Applied Biosystems 
(Forster City, U.S.A.).
Cell treatment and RNA isolation
Human prostate cancer cell line LNCaP clone FGC 
( American Type Culture Collection) was maintained 
in phenol red RPMI-1640 medium, 5 ug/ml insulin 
and antibiotics (penicillin 100 units/ml, streptomycin 
100 ug/ml) at 37 °C in a humid atmosphere with 5% 
CO2. Serum supplemented in the medium was 10% 
FBS otherwise 10% DCC-FBS as indicated. Cells 
were grown to 50% conﬂ  uence and treated with 
vitamin D3 or/and other reagents. Total cellular RNA 
was isolated with TRIzoL reagent following the 
instructions from the manufacturer.
Quantitative real-time PCR analysis 
and primer design
Quantitative Real-time PCR was performed in ABI 
PRISM 7000 Detection System (Applied Biosys-
tems, U.S.A.). cDNA was synthesised using High 
Capacity Archive Kit (Applied Biosystems, 
U.S.A.) and was used as template for Quantitative 
Real-time PCR using SYBR Green PCR Master 
Mix kit (Applied Biosystems, U.S.A.). Primers 
were designed using Primer Express v2.0 software 
(Perkin-Elmer Applied Biosystems, Foster City, 
C.A.). BLASTn searches were performed to ensure 
that the primers were gene speciﬁ  c. The expression 
of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used for normalization. Nucleotide 
sequences for primers are as following: GAPDH 
(NM_002046) Forward: 5'-CCACATCGCT-
CAGACACCAT-3', Reverse: 5'-ACCAGGC-
GCCCAATACG-3'; ABCA1 (NM_005502) 
Forward: 5'-GAGCACCATCCGGCAGAA-3', 
Reverse: 5'-CTCCGCCTTCACGTGCTT-3'; 
ABCG1 (NM_207630) Forward: 5'-GCTGCT-
GCCGCATCTCA-3', Reverse: 5'-TTCCCTTCT-
GCCTTCATCCTT-3'; LXRα (HSU22662) 
Forward: 5'-CATGCCTACGTCTCCATCCA-3', 
Reverse: 5'-CGGAGGCTCACCAGTTTCA-3'; 
LXRβ (HSU07132) Forward: 5'-GATGTCCCAG-
GCACTGATGA-3', Reverse: 5'-CTG-
GTTCCTCTTCGGGATCTG-3'; VDR 
(NM_000376) Forward: 5'-CCTTCACCATG-
GACGACATG-3', Reverse: 5'-CGGCTTTGGT-
CACGTCACT-3'; CYP24 (NM_000782) Forward: 
5'-GCCCAGCCGGGAACTC-3', Reverse: 
5'-AAATACCACCATCTGAGGCGTATT-3’
Cell growth assay
LNCaP cells were treated with hormones and/or 
other reagents for 0, 4 and 7 days in CellBIND 6-well 
plates (Sigma-Aldrich). Glybenclamide was given 
at a concentration which almost completely blocked 
the activity of ABCA1 (Becq et al. 1997). Each treat-
ment was repeated three times. Glybenclamide was 
dissolved in dimethyl sulfoxide (DMSO) and all the 
other reagents in absolute ethanol. Control cells were 
treated with 0.2% ethanol plus 0.1% DMSO. Cell 
growth was analysed with crystal violet staining as 
described earlier (Kueng et al. 1989). Brieﬂ  y, cells 
were ﬁ  xed by addition of gultaraldehyde to the cell 
culture with a ﬁ  nal concentration of 1% and shaking 
at 200 rpm for 15 min, then washed with tap water 
and air-dried over night. 0.1% crystal violet solution 
was added to stain the ﬁ  xed cells for 20 min with 
shaking at 200 rpm. Excess dye was removed by 
extensive washing with tap water. The plates were 
air-dried over night. 10% acetic acid was used to 
withdraw cell-bound dye. The optical density of 
extracted dye was measured in 96-well plates at 
590 nm by Microplate Reader (Wallac, victor 1420 
multilabel counter, Turku, Finland). Final data was 
presented as percentage absorbance to negative 
control cells of corresponding treatment period.
Statistical analysis
Data of real-time PCR are expressed as the mean 
values ± SD. Signiﬁ  cance was assessed using the 99
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Student’s paired t test. *p   0.05 was considered 
as signiﬁ  cant, **p   0.001 as highly signiﬁ  cant 
and p   0.05 as not signiﬁ  cant (NS).
Results
Down-regulation of ABCA1 mRNA 
by calcitriol in LNCaP cells
To test whether calcitriol has any effect on the 
expression of ABCA1 mRNA, prostate cancer 
LNCaP cells were treated with calcitriol and the 
mRNA expression level was analyzed by Quan-
titative Real-Time PCR. The results show that 
the expression of ABCA1 mRNA is dose depend-
ently inhibited by 1α,25(OH)2D3 (Fig. 1A). At 
10 nM, a signiﬁ  cant inhibition of ABCA1 mRNA 
expression begins at 6 hours. At 24 hours, the 
effect of 10 nM 1α,25(OH)2D3 is at the maximum 
(Fig. 1B).
Calcitriol inhibits ABCA1 mRNA 
induction by TO-901317
Because TO-901317 induces ABCA1 expression 
(Wu et al. 2004), we were interested to examine 
whether calcitriol had any effect on ABCA1 mRNA 
expression in the presence of TO-901317. Our 
results show that TO-901317 induces 14-fold 
(p = 0.0014) of ABCA1 mRNA expression and 
10 nM calcitriol with 10 uM TO-901317 results in 
a 47% (p = 0.017) decrease of it (Fig. 1C).
Effect of cycloheximide on calcitriol 
mediated inhibition of ABCA1 
mRNA expression
Next we studied whether the decrease of ABCA1 
mRNA effect of calcitriol was a direct effect. Our 
data show that in the presence of protein synthesis 
inhibitor, cycloheximide, calcitriol fails to 
decrease mRNA level of ABCA1 (Fig. 1D), sug-
gesting an indirect regulation of ABCA1 by cal-
citriol. In comparison, cycloheximide has no effect 
on TO-901317 mediated ABCA1 mRNA induction 
(Fig. 1D).
Effect of calcitriol and TO-901313 on 
LXRα, LXRβ and ABCG1 expression
Alike ABCA1, ABCG1 is also a LXR target gene. 
Thus, we studied whether calcitriol affected the 
mRNA expression of ABCG1. In addition, to test 
whether the regulation of ABCA1 by calcitriol is 
via the regulation of LXRα and LXRβ, the mRNA 
expression of these two genes were studied as well. 
At 24 hours, calcitriol has no effect on any of the 
three genes examined at different concentrations 
ranging from 0.1 nM to 100 nM (Fig. 2A). In 
comparison, TO-901317 signiﬁ  cantly increases 
53-fold (p = 0.03) of the expression of ABCG1 
mRNA (Fig. 2B). In the presence of calcitriol, 
TO-901317 increases ABCG1 expression 45-fold 
(p = 0.03) (Fig. 2B). There is no statistically sig-
niﬁ  cant difference between TO-901317 treatment 
alone and in combination with calcitriol (p = 0.58), 
implying calcitriol has no effect on TO-901317 
induced ABCG1 expression as well. Cyclohexi-
mide can not block the induction of ABCG1 by 
TO-901317 (Fig. 2B).
Effect of TO-901317 on CYP24 
and VDR expression
Studies described above deal with the effect of 
VDR ligand, calcitriol, on the mRNA expression 
of LXRs and their target genes. Next we were 
interested to investigate the other way around, 
which was to study whether LXR agonist, 
TO-901317, had any effect on the mRNA expres-
sion of VDR and its target gene CYP24. Our results 
show TO-901317 inhibits slightly but signiﬁ  cantly 
the VDR mRNA expression (Fig. 3A) and there is 
no statistically signiﬁ  cant difference between the 
TO-901317 treatment alone or in combination with 
calcitriol (data not shown). TO-901317 not only 
increases basal CYP24 mRNA expression 8-fold 
(p = 0.03) (Fig. 3A), but also enhances 10-fold 
(p   0.001) of calcitriol mediated induction of 
CYP24 expression (Fig. 3B).
Androgen-dependency of ABCA1 
expression
It has been reported that androgen inhibits ABCA1 
expression in LNCaP cells (Fukuchi et al. 2004a). 
Actions of vitamin D involve both androgen-
dependent and androgen-independent mechanisms 
(Zhao et al. 1997; Zhao et al. 1999; Zhao et al. 
2000). Thus we examined whether the inhibition 
of ABCA1 mRNA expression was androgen-
dependent. As a positive control, androgen was 
included in our study. We also ﬁ  nd that androgen 
inhibits the expression of ABCA1 (Fig. 4B). In the 100
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medium supplemented with the normal serum, 
androgen receptor antagonist, bicalutamid, causes 
a significant increase of ABCA1 expression 
(Fig. 4A). Despite the presence of bicalutamide, 
calcitriol decreases signiﬁ  cantly the mRNA expres-
sion level of ABCA1 to the level with calcitriol 
treatment alone (Fig. 3A). Furthermore, in medium 
containing dextran-charcoal-stripped serum (low 
androgen serum), which is referred to DCC 
medium herein, 10 nM calcitriol still signiﬁ  cantly 
decreases ABCA1 expression by 64% (p   0.001) 
(Fig. 4B). 
Figure 1. Down-regulation of ABCA1 mRNA expression by calcitriol in LNCaP cells. (A) LNCaP cells were treated with 0.2% ethanol and 
different doses of calcitriol for 24 hours or (B) with 0.2% ethanol and 10 nM calcitriol for different period of time. (C) Cells were treated with 0.2% 
ethanol, 10 nM 1α,25(OH)2D3, 10 uM TO-901317 and 1α,25(OH)2D3 plus TO-901317. The inhibition of ABCA1 occurred also in the presence 
of TO-901317. (D) Cells were treated with 0.2% ethanol, 10 nM 1α,25(OH)2D3, 10 ug/ml cycloheximide, 10 uM TO-901317 and 1α,25(OH)2D3/ 
TO-901317 plus cycloheximide. Cycloheximide has no effect on TO-901317 mediated ABCA1 mRNA induction but blocked the inhibition effect 
of calcitriol. Relative ABCA1 mRNA expression was analysed by Quantitative Real-Time PCR (n = 3, *p   0.05, **p   0.001).
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Figure 2. Effects on the mRNA expression of LXRα, LXRβ and ABCG1 by calcitriol, TO-901317 and cycloheximide. LNCaP cells were treated 
for 24 hours with 0.2% ethanol, and (A) different concentrations of calcitriol (B) 10 uM TO-901317, 10 ug/ml cycloheximide, TO-901317 plus 
calcitriol and/or plus cycloheximide. Calcitriol has no effect on the mRNA expression of LXRα, LXRβ and ABCG1 whether TO-901317 is 
present (B) or not (A). Relative mRNA expression were analysed by Quantitative Real-Time PCR (n = 3, *p   0.05, **p   0.001).
Effect of calcitriol, TO-901317, 
DHT and glybenclamide 
on LNCaP proliferation
Finally, we were interested to study whether the 
inhibition of ABCA1 by calcitriol rendered any 
physiological effect regarding LNCaP growth, and 
whether calcitriol and DHT had the same effect 
on LNCaP cell proliferation when they were indi-
vidually co-treated with glybenclamide or 
TO-901317. Figure 5 shows that day4 and day7 
treatments have the same trend for each treatment 
indicated. In comparison to the negative control, 
Figure 3. Effects on the mRNA expression of CYP24 and VDR by TO-901317. LNCaP cells were treated with 0.2% ethanol, 10 nM calcitriol 
and 10 uM TO-901317 alone or in combination for 24 hours. TO-901317 inhibits VDR but induces basal CYP24 expression (A) as well as 
calcitriol mediated CYP24 induction (B). Relative mRNA expression were analysed by Quantitative Real-Time PCR (n = 3, *p   0.05, 
**p   0.001).
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Figure 4. Androgen-dependency of ABCA1 expression. LNCaP cells were treated for 24 hours with 0.2% ethanol, 10 nM calcitriol, 1 uM 
bicalutamide and calcitriol plus bicalutamide in normal medium (A), or with 10 nM calcitriol, 10 nM DHT and calcitriol plus DHT in DCC 
medium (B). Relative mRNA expression was analyzed by Quantitative Real-Time PCR (n = 3, *p   0.05, **p   0.001).
The increase of CYP24 mRNA by TO-901317 is 
not due to an increase of VDR. Calcitriol has no 
effects on LXRα and LXRβ expression, suggest-
ing that the inhibition of ABCA1 by calcitriol is 
not due to the down-regulation of these two tran-
scription factors. Previously, Takahide M et al. 
(Jiang et al. 2006) reported that 1α,25(OH)2D3 
blunted the LXRα-mediated induction of choles-
terol 7alpha-hydroxylase mRNA in H4IIE rat 
hepatoma cells. Cholesterol 7alpha-hydroxylase 
is the rate-limiting enzyme in the catabolism of 
cholesterol to bile acid (Hubacek and Bobkova, 
2006; Shefer et al. 1970) and it is stimulated by 
oxysterol receptor, LXRα (Chiang et al. 2001; 
Peet et al. 1998). Thus, it appears that VDR 
negatively regulates LXR mediated induction of 
ABCA1 as well as cholesterol 7alpha-hydroxylase, 
which are all involved in cholesterol efﬂ  ux and 
bile acid synthesis. On the other hand, we ﬁ  nd that 
TO-901317 slightly but signiﬁ  cantly inhibits VDR 
expression and up-regulates CYP24, which is up-
regulated by VDR (Chen and DeLuca, 1995). 
CYP24 is an enzyme responsible for inactivating 
of active vitamin D metabolites such as 
1,25α(OH)2D3 and 25(OH)D3 (Chen et al. 1993; 
which is 100% in relative absorbance, both 
calcitriol and DHT decreases LNCaP cell growth. 
At day7, when each of calcitriol and DHT is co-
treated with glybenclamide, cell growth is signiﬁ  -
cantly decreased compared to their own treatment 
respectively. However, when co-treated with 
TO-901317, calcitriol shows no signiﬁ  cant differ-
ence and DHT shows signiﬁ  cant decrease of cell 
proliferation compared with each hormone treat-
ment alone, respectively. TO-901317 and glyben-
clamide individually decreases LNCaP cell growth. 
Their co-treatment further decreases cell prolif-
eration, which remains unchanged whether when 
calcitriol or DHT is added.
Discussion
In this study, we report for the ﬁ  rst time, that cal-
citriol inhibits the mRNA expression of ABCA1. 
Calcitriol not only decreases basal level of ABCA1 
expression, but also inhibits the LXR agonist, 
TO-901317, mediated induction of ABCA1. On 
the other hand, TO-901317 alone increases CYP24 
mRNA expression and, furthermore, it enhances 
calcitriol mediated induction of this gene. 
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Ohyama et al. 1993). This suggests that LXR 
agonist might play a role in the negative regulation 
of the actions of VDR ligand. Stimulated by a 
growing body of preclinical evidence that vitamin 
D inhibits the proliferation of prostate cancer, 
clinical trials of calcitriol in prostate cancer 
patients have been carried out since the 1990s 
(Beer, 2003). On the other hand, our present study 
shows that TO-901317 inhibited LNCaP cell pro-
liferation and Liao et al. (Fukuchi et al. 2004a) 
ﬁ  nd that knockdown of ABCA1 expression by 
RNA interference in androgen-dependent cells 
increased their rate of proliferation. Based on their 
study they proposed a potential of use of LXR 
signaling as a therapeutic target in prostate and 
other cancers (Chuu et al. 2007). Our present study 
suggests a mutual negative regulation of the 
actions of the ligands of VDR and LXR. This 
implies that cautions have to be taken whether 
which of the VDR or LXR signaling was consid-
ered for the therapeutic target in prostate cancer.
ABCA1 has been reported to be regulated by 
androgen in LNCaP cells (Fukuchi et al. 2004a). 
Our study shows in normal medium, AR antagonist, 
bicalutamide, increases ABCA1 level and calcitriol 
acts as an antagonist of bicalutamide. Furthermore, 
calcitriol signiﬁ  cantly inhibits ABCA1 in low-
androgen-serum containing medium. This suggests 
that the inhibition of ABCA1 by calcitriol is most 
probably androgen-independent.
ABCA1 is a cholesterol exporter (Oram and 
Heinecke, 2005; Venkateswaran et al. 2000). 
Figure 5. Effect of calcitriol, TO-901317, DHT and glybenclamide on LNCaP proliferation. LNCaP cells were treated for 0, 4 and 7 days (data 
at Day 4 and 7 are given) with 1.10 uM TO-901317; 2.100 uM glybenclamide; 3.10 uM TO-901317+100 uM glybenclamide; 4.10 nM 1α,25(OH)2D3; 
5.10 nM 1α,25(OH)2D3+100 uM glybenclamide; 6.10 nM 1α,25(OH)2D3 +10 uM TO-901317; 7.10 nM 1α,25(OH)2D3+10 uM TO-901317+100 uM 
glybenclamide; 8.10 nM DHT; 9.10 nM DHT+100 uM glybenclamide; 10.10 nM DHT+10 uM TO-901317; 11.10 nM DHT+10 uM TO-901317+100 uM 
glybenclamide. Negative control cells were treated with 0.2% ethanol + 0.1% DMSO. Crystal violet staining analysis was used to measure 
the absolute absorbance which reﬂ  ects absolute cell number. Data shown is relative absorbance (Relative absorbance = (absolute 
absorbance)compound / (absolute absorbance)ethanol * 100). Day4 and day7 treatments have the same trend for each treatment indicated. (n = 3, 
*p   0.05, **p   0.001).
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It may be involved in cell proliferation as reported 
earlier (Fukuchi et al. 2004a), which showed spe-
ciﬁ  c knock-down of ABCA1 expression by RNA 
interference resulted in an increase of LNCaP 
proliferation. The same research group (Fukuchi 
et al. 2004a) demonstrated that DHT inhibited 
ABCA1 expression and this regulation is involved 
in DHT mediated LNCaP proliferation. Here we 
ﬁ  nd that calcitriol also inhibits the expression of 
ABCA1. Thus, we were interested to test whether 
the inhibition of ABCA1 by calcitriol had effect 
on cell proliferation, and we included DHT as a 
parallel in our cell growth assay. We did not 
observe an increase of cell proliferation after 
glybenclamide treatment as expected, given that 
knock-down of ABCA1 increases LNCaP prolif-
eration (Fukuchi et al. 2004a). This might be 
because glybenclamide can inhibit a broad range 
of ABC transporters, including ABCA1 and cystic 
fibrosis transmembrane conductance regulator 
(Hasko et al. 2002). The ﬁ  nal output of speciﬁ  c 
blocking of ABCA1 by glybenclamide thus is not 
seen here. This explains why co-treatment of 
glybenclamide and TO-901317 dose not give a cell 
growth level which is in between of the level from 
each reagent treatment alone, but it is even further 
decreased compared to either of the reagent treat-
ment. Thus, here we could not draw any conclusion 
by comparing calcitriol treatment and calcitriol 
plus glybenclamide treatment. However, when 
each of calcitriol and DHT was co-treated with 
glybenclamide, cell-growth was significantly 
decreased compared to their own treatment respec-
tively. This suggests that the regulation of LNCaP 
cell proliferation by calcitriol may involve its 
inhibition of ABCA1, which has some similarity 
to DHT, given that inhibition of ABCA1 by DHT 
is involved in its regulation of LNCaP proliferation 
(Fukuchi et al. 2004a). However, when co-treated 
with TO-901317, calcitriol shows no signiﬁ  cant 
difference whereas DHT shows signiﬁ  cant decrease 
of cell proliferation when compared with each 
hormone treatment alone, respectively, suggesting 
that DHT is more involved in LXR agonist related 
cell growth regulation than calcitriol does.
The inhibition of ABCA1 mRNA by calcitriol 
occurred not earlier than at 6 hours, indicating that 
the effect might be indirect. This was conﬁ  rmed 
by using protein synthesis inhibitor, cyclohexi-
mide, which blocked calcitriol mediated decrease 
of ABCA1 mRNA. In comparison, it failed to block 
LXR agonist mediated induction of ABCA1 and 
ABCG1, suggesting ABCA1 and ABCG1 are 
directly regulated by LXR, which have been 
reported before (Costet et al. 2000; Karten et al. 
2006). The testing of ABCA1 and ABCG1 serves 
as positive control in our experiments and the 
testing results indicate that our experimental 
system works normally.
In conclusion, we report for the ﬁ  rst time that 
VDR ligand, calcitriol, inhibits ABCA1 mRNA 
expression and LXR agonist, TO-901317, induces 
CYP24 mRNA expression, suggesting an interaction 
between calcitriol and TO-901317 in prostate cancer 
cells, which implicates an association between VDR 
and LXR in prostate cancer. The inhibition of 
ABCA1 by calcitriol seems to be androgen-
independent and might be involved in LNCaP 
proliferation, which has at least some similarity to 
DHT. Studying and understanding of the interaction 
between VDR and LXR/AR is critical for rational 
design of future clinical trials with vitamin D com-
pounds for prevention and treatment of associated 
cancers such as prostate cancer.
Acknowledgement
We are grateful to Pasi Pennanen for valuable 
advices, to Mrs. Arja Ahola, Miss Marianne 
Kuuslahti, Mrs. Hilkka Mäkinen and Mrs. Mirja 
Hyppönen for their excellent technical assistance, 
to Leo Pharmaceuticals (Ballerup, Denmark) for 
the generous gift of 1α,25(OH)2D3. This work was 
supported by grants from Drug Discovery Gradu-
ate School (University of Turku), Tampere 
University Hospital, the Finnish Cancer Founda-
tion and the Academy of Finland.
References
Becq, F., Hamon, Y., Bajetto, A. et al. 1997. ABC1, an ATP binding cassette 
transporter required for phagocytosis of apoptotic cells, generates a 
regulated anion ﬂ  ux after expression in Xenopus laevis oocytes. 
J. Biol. Chem., 272:2695–9.
Beer, T.M. 2003. Development of weekly high-dose calcitriol based therapy 
for prostate cancer. Urol. Oncol., 21:399–405.
Brooks-Wilson, A., Marcil, M., Clee, S.M. et al. 1999. Mutations in ABC1 
in Tangier disease and familial high-density lipoprotein deﬁ  ciency. 
Nat. Genet., 22:336–45.
Chen, K.S., Prahl, J.M. and DeLuca, H.F. 1993. Isolation and expression 
of human 1,25-dihydroxyvitamin D3 24-hydroxylase cDNA. Proc. 
Natl. Acad. Sci., U.S.A., 90:4543–7.
Chen, K.S. and DeLuca, H.F. 1995. Cloning of the human 1 alpha, 
25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and iden-
tiﬁ  cation of two vitamin D-responsive elements. Biochim. Biophys. 
Acta., 1263:1–9.
Chiang, J.Y., Kimmel, R. and Stroup, D. 2001. Regulation of cholesterol 
7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan 
receptor (LXRalpha). Gene, 262:257–65.105
Calcitriol and TO-901317 interact in human prostate cancer LNCaP cells
Gene Regulation and Systems Biology 2008:2 
Chuu, C.P., Hiipakka, R.A., Kokontis, J.M. et al. 2006. Inhibition of tumor 
growth and progression of LNCaP prostate cancer cells in athymic mice 
by androgen and liver X receptor agonist. Cancer Res., 66:6482–6.
Chuu, C.P., Kokontis, J.M., Hiipakka, R.A. et al. 2007. Modulation of liver 
X receptor signaling as novel therapy for prostate cancer. J. Biomed 
Sci., 14:543–53.
Costet, P., Luo, Y., Wang, N. et al. 2000. Sterol-dependent transactivation 
of the ABC1 promoter by the liver X receptor/retinoid X receptor. 
J. Biol. Chem., 275:28240–5.
Dunlop, T.W., Vaisanen, S., Frank, C. et al. 2005. The human peroxisome 
proliferator-activated receptor delta gene is a primary target of 
1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J. Mol. 
Biol., 349:248–60.
Fukuchi, J., Hiipakka, R.A., Kokontis, J.M. et al. 2004a. Androgenic sup-
pression of ATP-binding cassette transporter A1 expression in LNCaP 
human prostate cancer cells. Cancer Res., 64:7682–5.
Fukuchi, J., Kokontis, J.M., Hiipakka, R.A. et al. 2004b. Antiproliferative 
effect of liver X receptor agonists on LNCaP human prostate cancer 
cells. Cancer Res., 64:7686–9.
Hasko, G., Deitch, E.A., Nemeth, Z.H. et al. 2002. Inhibitors of ATP-binding 
cassette transporters suppress interleukin-12 p40 production and 
major histocompatibility complex II up-regulation in macrophages. 
J. Pharmacol. Exp. Ther., 301:103–10.
Hubacek, J.A. and Bobkova, D. 2006. Role of cholesterol 7alpha-hydroxy-
lase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol 
lowering. Mol. Diagn. Ther., 10:93–100.
Jiang, W., Miyamoto, T., Kakizawa, T. et al. 2006. Inhibition of LXRalpha 
signaling by vitamin D receptor: possible role of VDR in bile acid 
synthesis. Biochem. Biophys. Res. Commun., 351:176–84.
Karten, B., Campenot, R.B., Vance, D.E. et al. 2006. Expression of ABCG1, 
but Not ABCA1, Correlates with Cholesterol Release by Cerebellar 
Astroglia. J. Biol. Chem., 281:4049–57.
Kueng, W., Silber, E. and Eppenberger, U. 1989. Quantiﬁ  cation of cells 
cultured on 96-well plates. Anal. Biochem., 182:16–9.
Maxﬁ  eld, F.R. and Tabas, I. 2005. Role of cholesterol and lipid organization 
in disease. Nature, 438:612–21.
Ohyama, Y., Noshiro, M., Eggertsen, G. et al. 1993. Structural characteriza-
tion of the gene encoding rat 25-hydroxyvitamin D3 24-hydroxylase. 
Biochemistry, 32:76–82.
Oram, J.F. and Heinecke, J.W. 2005. ATP-binding cassette transporter A1: 
a cell cholesterol exporter that protects against cardiovascular disease. 
Physiol. Rev., 85:1343–72.
Peet, D.J., Turley, S.D., Ma, W., Janowski, B.A. et al. 1998. Cholesterol 
and bile acid metabolism are impaired in mice lacking the nuclear 
oxysterol receptor LXR. alpha. Cell., 93:693–704.
Rust, S., Rosier, M., Funke, H. et al. 1999. Tangier disease is caused by 
mutations in the gene encoding ATP-binding cassette transporter 1. 
Nat. Genet., 22:352–5.
Serfaty-Lacrosniere, C., Civeira, F., Lanzberg, A. et al. 1994. Homozygous 
Tangier disease and cardiovascular disease. Atherosclerosis, 
107:85–98.
Shefer, S., Hauser, S., Bekersky, I. et al. 1970. Biochemical site of regulation 
of bile acid biosynthesis in the rat. J. Lipid Res., 11:404–11.
Wang, J.H. and Tuohimaa, P. 2007. Regulation of 17beta-hydroxysteroid 
dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR. agonist 
and 5alpha-dihydrotestosterone in human prostate cancer cells. 
J. Steroid Biochem. Mol. Biol., 107:100–5.
Wang, T.T., Tavera-Mendoza, L.E., Laperriere, D. et al. 2005. Large-scale 
in silico and microarray-based identification of direct 1,25-
dihydroxyvitamin D3 target genes. Mol. Endocrinol., 19:2685–95.
Venkateswaran, A., Lafﬁ  tte, B.A., Joseph, S.B. et al. 2000. Control of cel-
lular cholesterol efﬂ  ux by the nuclear oxysterol receptor LXR. alpha. 
Proc. Natl. Acad. Sci. U.S.A., 97:12097–102.
Wood, R.J., Tchack, L., Angelo, G. et al. 2004. DNA microarray analysis 
of vitamin D-induced gene expression in a human colon carcinoma 
cell line. Physiol. Genomics, 17:122–9.
Wu, J., Zhang, Y., Wang, N. et al. 2004. Liver X receptor-alpha mediates 
cholesterol efﬂ  ux in glomerular mesangial cells. Am. J. Physiol. Renal 
Physiol., 287:F886–895.
Zhao, X.Y., Ly, L.H., Peehl, D.M. et al. 1997. 1alpha,25-dihydroxyvitamin 
D3 actions in LNCaP human prostate cancer cells are androgen-
dependent. Endocrinology, 138:3290–8.
Zhao, X.Y., Ly, L.H., Peehl, D.M. et al. 1999. Induction of androgen recep-
tor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in 
LNCaP human prostate cancer cells. Endocrinology, 140:1205–12.
Zhao, X.Y., Peehl, D.M., Navone, N.M. et al. 2000. 1alpha,25-
dihydroxyvitamin D3 inhibits prostate cancer cell growth by 
androgen-dependent and androgen-independent mechanisms. 
Endocrinology, 141:2548–56.